Gene-sequencing technology producer Axbio raised nearly $100m in a round co-led by AstraZeneca-CICC Investment Fund while Eli Lilly helped Forbion Growth Opportunities Fund II to a $504m first close.
Funding AstraZeneca-CICC Investment Fund, the $1bn fund formed by pharmaceutical firm AstraZeneca and investment bank China International Capital Corporation, co-led a series B round for China-based gene-sequencing technology developer Axbio sized at almost $100m yesterday. The round was co-led with Yunfeng Capital and also featured CBC Group, CMG-SDIC Capital and 5Y Capital. Funds Another pharmaceutical…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
